Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of perioperative chemotherapy for esophageal cancer

Next Previous
Trial Profile

Phase II trial of perioperative chemotherapy for esophageal cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Adenosquamous carcinoma; Basal cell cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms PIECE Trial

Most Recent Events

  • 07 Jun 2022 Status changed to completed, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Primary endpoint has been met (three-year relapse free survival) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top